Merck & Company Inc (MRK)vsPacira BioSciences, Inc. (PCRX)
MRK
Merck & Company Inc
$148.78
+0.54%
HEALTHCARE · Cap: $365.34B
PCRX
Pacira BioSciences, Inc.
$25.12
-1.72%
HEALTHCARE · Cap: $971.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8821% more annual revenue ($66.57B vs $746.16M). MRK leads profitability with a 4.8% profit margin vs 2.0%. MRK appears more attractively valued with a PEG of 2.76. PCRX earns a higher WallStSmart Score of 42/100 (D).
MRK
Hold36
out of 100
Grade: F
PCRX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.2%
Fair Value
$83.04
Current Price
$148.78
$65.74 premium
Margin of Safety
+87.9%
Fair Value
$179.51
Current Price
$25.12
$154.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 2.2% — below average capital efficiency
2.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PCRX
The strongest argument for PCRX centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PCRX
The primary concerns for PCRX are Altman Z-Score, Market Cap, Return on Equity. A P/E of 68.6x leaves little room for execution misses. Thin 2.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
PCRX carries more volatility with a beta of 0.27 — expect wider price swings.
PCRX is growing revenue faster at 6.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PCRX scores higher overall (42/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Pacira BioSciences, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?